Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Lifecore Biomedical, Inc. (LFCR) vs Organogenesis (ORGO)

Lifecore Biomedical, Inc. and Organogenesis are both Drug Manufacturers Specialty & Generic companies. Organogenesis is the larger, with a market value of $207.1M against $162.4M — 1.3× the size. Organogenesis grew revenue faster over the last twelve months: 6.50% against −10.0%. Organogenesis has the higher net margin (−22.2% vs −37.5%) and the lower return on invested capital (−20.0% vs −2.80%). Across the 18 metrics below, Organogenesis leads on 11 and Lifecore Biomedical, Inc. on 7.

Valuation

Metric LFCR ORGO Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.32 0.39 2.25
P/B n/m 1.22 1.90
Price to free cash flow n/m 8.64 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 2.73 0.33 2.56
Earnings yield (23.10%) (60.71%) (2.99%)
Free cash flow yield (3.21%) 11.57% 0.00%

Profitability

Metric LFCR ORGO Drug Manufacturers Specialty & Generic median
Gross margin 26.86% 70.35% 53.94%
Operating margin (6.89%) (7.84%) 0.00%
Net margin (37.54%) (22.23%) 0.00%
Free cash flow margin (4.24%) 4.56% 0.00%
Return on equity 201.15% (53.31%) (0.40%)
Return on assets (19.32%) (23.44%) (3.32%)
Return on invested capital (2.80%) (19.97%) 0.00%

Growth

Metric LFCR ORGO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (10.03%) 6.50% 10.01%
EPS growth (last fiscal year) (439.33%) 1,600.00% —
Revenue growth, 5-year CAGR (4.24%) 10.77% 6.74%
Net income growth, 5-year CAGR 0.00% 3.04% 0.00%

Health

Metric LFCR ORGO Drug Manufacturers Specialty & Generic median
Debt to equity 11.50 0.07 0.05
Current ratio 3.87 3.52 2.31
Net debt to EBITDA (15.59) (1.14) 0.85

Dividend

Metric LFCR ORGO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric LFCR ORGO Drug Manufacturers Specialty & Generic median
Market cap 162.39m 207.13m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack